

Award Number: W81XWH-FE-EGH

TITLE: *[Illegible text]*

PRINCIPAL INVESTIGATOR: *[Illegible name]* *

CONTRACTING ORGANIZATION: *[Illegible organization name]*

REPORT DATE: *[Illegible date]*

TYPE OF REPORT: *[Illegible type]*

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE (DD-MM-YYYY) September 2013		2. REPORT TYPE Final		3. DATES COVERED (From - To) 1 March 2011 - 31 August 2013	
4. TITLE AND SUBTITLE Identification of Small Molecule Inhibitors of microRNA Involved in Chemoresistance and Cancer Stem Cells for Ovarian Cancer Intervention				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-11-1-0223	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Jin Cheng E-Mail: Jin.Cheng@moffitt.org				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) H. Lee Moffitt Cancer Center and Research Tampa, FL 33512				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT <p>During last year, we have characterized a small molecule inhibitor (MIR214-I) of miR-214. MIR214-I was found to specifically bind to miR-214 in vitro and in vivo. Furthermore, MIR214-I induces programmed cell death and inhibits ovarian cancer stem cell renewal in ovarian cancer cells expressing high levels of miR-214. In addition, MIR214-I selectively reduces tumor growth in xenograft model. Notably, MIR214-I synergizes with cisplatin and overcomes cisplatin resistance.</p>					
15. SUBJECT TERMS microRNA, small molecule inhibitor, ovarian cancer, chemoresistance					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 12	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

Introduction.....	4
Body.....	4
Key Research Accomplishments.....	9
Reportable Outcomes.....	9
Conclusions.....	11
References.....	11
Appendices.....	12

Introduction

Three tasks have been proposed in this project: 1) Identify small molecule inhibitors of miR-19a/b and miR-221/222 using cell-based HTS assay 2) Determine the specificity of miR-19a/b, miR-214 and miR-221/222 inhibitors identified from Aim 1 and 3) Evaluate the small molecule inhibitors of miR-19a/b, miR-214 or miR-221/222 in overcoming ovarian cancer chemoresistance in cell culture and animal mode.

Body:

1. Characterization of miR-214 inhibitor *in vitro*

During last year, we have characterized a miR-214 inhibitor, namely MCCRI (Fig. 1A). We have previously reported that miR-214, miR-155, miR-221/222 and miR-29 target PTEN, FOXO3a, ER α and CDK6 by direct interaction with 3'UTR of the mRNAs, respectively (1-4). To determine MCCRI specificity, luciferase assay was performed in ovarian surface epithelial T80 cells which were transfected with pMIR-3'UTR-PTEN/pre-miR214, pMIR-3'UTR-FOXO3a/pre-miR155, pMIR-3'UTR-ER α /pre-miR221 or pMIR-3'UTR-CDK6/pre-miR29. After incubation for 48 h, cells were treated with and without MCCRI for 6 h and then subjected to luciferase assay. Fig. 1B shows that MCCRI only inhibits miR-214-repressed pMIR-3'UTR-PTEN without significant effects on pMIR-3'UTR-FOXO3a/pre-miR155, pMIR-3'UTR-ER α /pre-miR221 or pMIR-3'UTR-CDK6/pre-miR29, suggesting that MCCRI specifically targets miR-214.




Figure 1. miR-214 inhibitor MCCRI specifically inhibits miR-214. (A) Chemical structure of miR-214 inhibitor MCCRI. (B) Luciferase reporter assay. Human immortalized ovarian surface epithelial T80 cells were transfected with pMIR-reporters which contain 3'UTR of PTEN, CDK6, ER α and FOXO3a and corresponding individual pre-miR as well as control oligo and β -gal. After 48 h of incubation, cells were treated with and without MCCRI for 6 h. Luciferase assay was performed and the luciferase activity was normalized to β -gal. Experiments were repeated 3 times in triplicates. Note: MCCRI only abrogated miR-214-repressed pMIR-PTEN reporter activity.

In addition, MCCRI contains an amino group which allows immobilizing MCCRI on Sepharose beads (GE Healthcare) through covalent linkage using its amino group (5). Thus, we performed *in vitro*

binding assay to determine if MCCRI directly binds to miR-214. NHS-activated Sepharose was equilibrated in DMSO and then incubated with MCCRI and other 2 unrelated compounds (e.g. Akt inhibitors API-1 and API-2), which also contain amino group (5, 6), as controls. Subsequently, the coupled affinity Sepharose beads were incubated with biotin-labeled pre-miR-214. Following washes, the products were eluted, separated on a PAGE gel and then detected. As shown in Fig. 2, pre-miR-214 was only eluted and detected in MCCRI-coupled Sepharose beads, indicating that MCCRI directly binds to miR-214.




Figure 2. MCCRI directly binds to miR-214. The indicated compounds were immobilized on NHS-activated Sepharose beads and then incubated with biotin-labeled miR-214. After wash and elution, the eluted products were detected with biotin/streptavidin detection kit.

Moreover, we have examined the effect of MCCRI on ovarian cancer cell death. Two miR-214-high (A2780CP and OVCAR-8) and two miR-214-low (OV2008 and OVCAR-3) ovarian cancer cell lines were treated with increasing concentration of MCCRI. Cell viability was evaluated after 36 h of treatment. Fig. 3A shows that MCCRI preferentially inhibits the cell survival in miR-214-high cells. Furthermore, Western blot analysis revealed that MCCRI abrogated miR-214-repressed PTEN and p53 expression (Fig. 3B).

Previous studies have shown that miR-214 promotes cell migration and invasion (7, 8). Therefore, we assessed the effects of MCCRI on miR-214-induced cell migration and invasion. Two chamber, with and without matrigel insert, assay revealed that expression of miR-214 promoted ovarian cell migration and invasion which were largely inhibited by MCCRI (Fig. 4).




Figure 3. MCCRI selectively inhibits cell survival in miR-214-high ovarian cancer cells. (A) Indicated cells were seeded in 96-well plates and treated with increasing concentrations of MCCRI. After treatment for 36 h, cell viability was evaluated. (B) A2780S cells were transfected with and without pre-miR-214. Following treatment with and without MCCRI, cells were subjected to Western blot analysis with indicated antibodies.




Figure 4. MCCRI abrogated miR-214-induced cell migration and invasion. A2780 cells were transfected with pre-miR-214 and control oligo. Following 48 h of incubation, cells were treated with and without MCCRI for 6 h and then subjected cell migration and invasion assay (upper panel). Bottom panels show the quantification.

2. MCCRI inhibits tumor growth in miR-214-high ovarian cancer cells *in vivo*.

We also examined anti-tumor activity of MCCRI in xenograft model. Briefly, 4 cell lines were subcutaneously injected to nude mice. When the tumor volumes reach approximately 100³ mm, the mice were divided into 2 groups (10 mice/group). One group was intraperitoneally treated with MCCRI and the other was administered with vehicle control for 27 days. While the anti-tumor activity of MCCRI is moderate, it significantly reduced tumor growth in miR-214-high cell lines (A2780CP and OVCAR-8) when compared to miR-214-low cells (OV2008 and SKOV3; Fig. 5). Western blot analysis also showed that MCCRI induced miR-214 target genes (Fig. 6). In addition, immunohistochemical staining revealed that the proliferation index was reduced in MCCRI-treated tumors (Fig. 7).




Figure 5. *MCCRI selectively inhibits tumor growth in miR-214-high ovarian cancer xenograft model. Indicated cell lines were subcutaneously injected to nude mice (5×10^6 /mouse). When the tumors reach $\sim 100 \text{ mm}^3$, the mice were intraperitoneally treated with MCCRI at 20 mg/kg (10 mice) or vehicle control daily (10 mice) for 27 days. Tumor growth was monitored and recorded every 3 days.*




Figure 6. *Western blot analysis of the representative xenograft tumors with indicated antibodies. Note: Socs1, p53 and PTEN are targets of miR-214.*




Figure 7. *Ki-67 staining of xenograft tumors from miR-214-low (SKOV3) and miR-214-high (OVCAR8) cells, which were treated with MCCRI and vehicle control.*

3. MCCRI inhibits ovarian cancer stem cell renewal and synergizes with cisplatin to overcome cisplatin resistance.

We have recently reported that miR-214 is a key regulator of ovarian cancer stem cell and plays a critical role in chemoresistance (8). We have also shown that ovarian cancer stem cells express much higher levels of miR-214 than non-cancer stem cells (8). Since cancer stem cells have been shown to contribute to chemoresistance and ovarian cancer relapse, we examined if MCCRI inhibited ovarian cancer stem cell self-renewal. Following treatment with and without MCCRI, C13 cells were labeled with ALDH1 labeling. Flow cytometry analysis showed that MCCRI significantly reduces ALDH1 positive cell (e.g., ovarian cancer stem cell) population (Fig. 8A). Furthermore, stem cell self-renewal assay (9) revealed that sphere formation was inhibited by MCCRI (Fig. 8B). More significantly, we found that MCCRI synergizes with cisplatin and overcomes cisplatin resistance (Fig. 9).




Figure 8. MCCRI inhibits ovarian cancer stem cells. (A) C13 cells were treated with and without MCCRI for 6 h and then were suspended in ALDEFUOR assay buffer containing an ALDH1 substrate, bodipy-aminoacetaldehyde, at 1.5 μ M and incubated for 1 h at 37 $^{\circ}$ C. Flow cytometry was performed and the data were analyzed FlowJo software (TreeStar). (B) Sphere assay. C13 cells were plated in ultra-negative attachment 6-well plates (Corning) at a density of 5000 viable cells/well. Cells were grown in a serum-free sphere culture medium (MammoCult, StemCell Technologies) supplemented with MammoCult proliferation supplements in for 12 days in the presence and absence of MCCRI. Sphere numbers were counted under microscopy.




Figure 9. MCCRI synergizes with cisplatin and overcomes cisplatin resistance. (A) Cisplatin-resistance ovarian cancer cell line C13 was treated with cisplatin or MCCRI alone and their combination at indicated concentration. After 72 hour of treatment, cell growth was examined by MTS assay (left). The effects of MCCRI and cisplatin combinations were evaluated with CalcuSyn software. CI analysis to determine synergy (defined as CI values < 1) was carried out (right). Each data point is the average of 3 wells each from 3 independent experiments.

Key Research Accomplishment

1. Identification of a miR-214 specific inhibitor, MCCRI.
2. MCCRI directly binds to miR-214.
3. MCCRI inhibits cell survival and tumor growth in ovarian cancer cell lines that express high levels of miR-214.
4. The properties of ovarian cancer stem cells were inhibited by MCCRI.
5. MCCRI synergizes with CDDP and overcomes CDDP resistance.

Reportable Outcomes

Publication:

1. Xu CX, Tan L, Yang H, Permut-Wey J, Kruk PA, Wenham RM, Nicosia SV, Lancaster JM, Sellers TA, Cheng JQ. MiR-214 Regulates Ovarian Cancer Cell Stemness by Targeting p53/Nanog. *J Biol Chem* 287:34970-8, 2012.
2. Jung HM, Phillips BL, Patel RS, Cohen DM, Jakymiw A, Kong WW, Cheng JQ, Chan EK. Keratinization-associated miR-7 and miR-21 regulate tumor suppressor reversion-inducing-cysteine-rich protein with kazal motifs (RECK) in oral cancer. *J Biol Chem*. 287:29261-72. 2012
3. Lin FC, Liu YP, Lai CH, Shan YS, Cheng HC, Hsu PI, Lee CH, Lee YC, Wang HY, Wang CH, Cheng JQ, Hsiao M, Lu PJ. RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells. *Oncogene*. 31:4302-16, 2012.

4. Han L, Yue X, Zhou X, Lan FM, You G, Zhang W, Zhang KL, Zhang CZ, Cheng JQ, Yu SZ, Pu PY, Jiang T, Kang CS. MicroRNA-21 Expression is regulated by β -catenin/STAT3 Pathway and Promotes Glioma Cell Invasion by Direct Targeting RECK. *CNS Neurosci Ther.* 18:573-583, 2012.
5. Koren J 3rd, Miyata Y, Kiray J, O'Leary JC 3rd, Nguyen L, Guo J, Blair LJ, Li X, Jinwal UK, Cheng JQ, Gestwicki JE, Dickey CA. Rhodacyanine derivative selectively targets cancer cells and overcomes tamoxifen resistance. *PLoS ONE.* 2012;7:e35566.
6. Park S, Kim D, Dan HC, Chen H, Testa JR, Cheng JQ. Identification of an Akt interaction protein, PHF20/TZP, that transcriptionally regulates p53. *J Biol Chem.* 287:11151-63, 2012.
7. Cui G*, Park S*, Badeaux AI*, Kim D*, Lee J, James R, Thompson JR, Yan F, Kaneko S, Yuan Z, Botuyan MV, Bedford MT†, Cheng JQ†, Mer G†. PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53. *Nat Struct Mol Biol.* 19:916-24, 2012 *equal contribution and †co-corresponding.
8. Lawrence HR, Martin MP, Luo Y, Pireddu R, Yang H, Gevariya H, Ozcan S, Zhu JY, Kendig R, Rodriguez M, Elias R, Cheng JQ, Sebt SM, Schonbrunn E, Lawrence NJ. Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors. *J Med Chem.* 55:7392-416, 2012.
9. Guo JP, Kim D, Gao J, Kurtyka C, Chen H, Yu C, Wu D, Mittal A, Beg AA, Chellappan SP, Haura EB, Cheng JQ. IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer. *Oncogene,* 32:151-9, 2013.
10. Kong W*, He L*, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM, Coppola D, Sellers TA, Djeu JY, Cheng JQ. Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer. *Oncogene* (In press).
11. Permuth-Wey J, Lawrenson K, Shen HC, Velkova A, Tyrer JP, Chen Z, Lin HY, Chen YA, Tsai YY, Qu X, Ramus SJ, Karevan R, Lee J, Lee N, Larson MC, Aben KK, Anton-Culver H, Antonenkova N, Antoniou AC, Armasu SM, Bacot F, Baglietto L, Bandera EV, Barnholtz-Sloan J, Beckmann MW, Birrer MJ, Bloom G, Bogdanova N, Brinton LA, Brooks-Wilson A, Brown R, Butzow R, Cai Q, Campbell I, Chang-Claude J, Chanock S, Chenevix-Trench G, Cheng JQ et al., Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nature Communication* (In press)
12. Guo JP*, Tian W*, Shu S, Xin Y., Shou C, Cheng JQ. IKBKE phosphorylation and degradation of FOXO3a in an Akt dispensable manner: A mechanism of IKBKE oncogenic function. *PLoS ONE*, (in press, *equal contribution).

Abstract/presentation

1. Jung HM, Patel RS, Cheng JQ, Chan EKL. Downregulated miR-375 in tongue cancer and its putative role as a tumor suppressor microRNA. AACR 102 Annual Meeting, 2011.
2. Richards EJ, Coppola M, Guo JP, Kong W, Cheng JQ. microRNA-641 activates MAPK by targeting NF1 and cooperates with its host gene AKT2 in human cancer. AACR Special Conference "Noncoding RNAs and Cancer", 2012
3. Permuth-Wey J, Lin HY, Tsai YY, Zhihua C, Chen YA, Barnholtz-Sloan J, Birrer MJ, Chanock S, Cramer DW, Cunningham JM, Fenstermacher D, Fridley B, Garcia-Closas M, Gayther SA, Gentry-Maharaj A, Gonzalez-Bosquet J, Iversen E, Jim H, McLaughlin J, Menon U, Monteiro A, Narod SA, Phelan CM, Ramus S, Risch H, Song H, Sutphen R, Terry KM, Tyrer J, Vierkant RA, Wentzensen N, Lancaster JM, Cheng JQ, Berchuk A, Pharoah PDP, Schildkraut JM, Goode EL, Sellers TA. MicroRNA binding site polymorphisms influence ovarian cancer risk in the collaborative oncological gene-environment study. AACR 103 Annual Meeting, 2012.

4. Guo JP, Kim D, Kurtyka C, Chen H, Wu D, Mittal A, Cheng JQ. IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer. AACR 103 Annual Meeting, 2012.
5. Kim D, Guo JP, Gao J, Yu C, Park J, Coppola D, Haura E, Cheng JQ. IKBKE/IKK ϵ is a prognostic marker and is required for KRAS-driven tumorigenicity in non-small cell lung cancer. AACR 103 Annual Meeting, 2012.
6. Kim D, Park S, Yan F, He L, Cheng JQ. Akt interacts and phosphorylates PHF20, a transcription factor binding to and inducing p53. AACR 103 Annual Meeting, 2012.
7. Kim D, Park S, Lee SH, Park JY, Cheng JQ. Frequent downregulation of NGB/GTPBP in lung cancer. AACR 103 Annual Meeting, 2012.
8. Jung HM, Patel RS, Cohen DM, Jakymiw A, Kong WM, Cheng JQ, Chan EKL. Subclassification of oral cancers using a miRNA-based combinatorial approach. AACR 103 Annual Meeting, 2012.
9. Guo JP, Coppola D, Cheng JQ. IKBKE activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 to sustain malignant transformation. AACR 103 Annual Meeting, 2012.
10. Xiangqian Zheng¹, Jianping Guo¹, Hua Yang¹, Lili He¹, Masayuki Kanai¹, Domenico Coppola¹, Ming Gao², Xiubao Ren², Jin Q. Cheng. Aurora-A is a determinant of tamoxifen resistance by phosphorylation and activation of ER α in breast cancer. AACR 104 Annual Meeting, 2013.
11. Yu Xin, Jianping Guo, Jin Q. Cheng. Small molecule inhibitors of IKBKE with antitumor activity in cancer cells overexpressing IKBKE. AACR 104 Annual Meeting, 2013.

Conclusion

1. Specific miR-214 inhibitor MCCRI has antitumor activity *in vitro* and *in vivo*.
2. MCCRI inhibits ovarian cancer stem cells and overcomes cisplatin resistance.

References

1. Yang H, Kong W, He L, Zhao JJ, O'Donnell JD, Wang J, Wenham RM, Coppola D, Kruk PA, Nicosia SV, Cheng JQ. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. *Cancer Res.* 68:425-33, 2008.
2. Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D, Cheng JQ. MicroRNA-155 regulates cell survival, growth and chemosensitivity by targeting FOXO3a in breast cancer. *J. Biol. Chem.* 285:17869-79, 2010.
3. Zhao JJ, Lin J, Lwin T, Yang H, Guo J, Kong W, Dessureault S, Moscinski LC, Reznia D, Dalton WS, Sotomayor E, Tao J, Cheng JQ. MicroRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in Mantle cell lymphoma. *Blood*, 115:2630-9, 2010.
4. Zhao JJ, Lin J, Yang H, Kong W, He L, Ma X, Coppola D, Cheng JQ. MicroRNA-221/222 negatively regulates ER α and associates with tamoxifen resistance in breast cancer. *J. Biol. Chem.* 283:31079-86, 2008.
5. Kim D, Sun M, He L, Zhou QH, Chen J, Sun XM, Bepler G, Sebti SM, Cheng JQ. A small molecule inhibits Akt through direct binding to Akt and preventing Akt membrane translocation. *J. Biol. Chem.* 285:8383-94, 2010.
6. Berndt N, Yang H, Trinczek B, Betzi S, Zhang Z, Wu B, Lawrence NJ, Pellicchia M, Schönbrunn E, Cheng JQ, Sebti SM. The Akt activation inhibitor TCN-P inhibits Akt phosphorylation by binding to the PH domain of Akt and blocking its recruitment to the plasma membrane. *Cell Death Differ.* 17:1795-804, 2010.

7. Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino E, Polisenio L, Haimovic A, Osella-Abate S, De Pittà C, Pinatel E, Stadler MB, Provero P, Bernengo MG, Osman I, Taverna D. microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. *EMBO J.* 30:1990-2007, 2011.
8. Xu CX, Tan L, Yang H, Permeth-Wey J, Kruk PA, Wenham RM, Nicosia SV, Lancaster JM, Sellers TA, Cheng JQ. MiR-214 Regulates Ovarian Cancer Cell Stemness by Targeting p53/Nanog. *J Biol Chem.* 287:34970-8, 2012.
9. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. *Cell.* 133:704-15, 2008.

Appendices

None